VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO Immuno-Oncology 2022 | What does the future hold for cellular therapies in solid tumors?

Michael Nishimura, PhD, Loyola University Chicago, Chicago, IL, comments on strategies to further enhance the usage of CAR-T cells in solid tumors. Current research on neoantigen-based CAR-T cells may improve efficacy in a hostile tumor microenvironment. Reducing immunogenicity will additionally reduce neurotoxicity and adverse events such as cytokine release syndrome (CRS), especially in anti-CD19 CAR-T cells. This interview took place at the ESMO Immuno-Oncology Congress 2022 in Geneva, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter